Boehringer Ingelheim Animal Health USA Inc., a subsidiary of the global pharmaceutical company Boehringer Ingelheim, is headquartered in the United States and operates extensively across North America. Founded in 1885, the company has established itself as a leader in the animal health industry, focusing on innovative solutions for both livestock and companion animals. With a diverse portfolio that includes vaccines, parasiticides, and therapeutics, Boehringer Ingelheim is renowned for its commitment to research and development, which drives the creation of unique products tailored to enhance animal well-being. The company’s dedication to advancing animal health has positioned it among the top players in the market, achieving significant milestones in veterinary medicine and animal care.
How does Boehringer Ingelheim Animal Health USA Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Boehringer Ingelheim Animal Health USA Inc.'s score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Boehringer Ingelheim Animal Health USA Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing its carbon footprint at this time. As a current subsidiary of Boehringer Ingelheim, any potential climate initiatives or emissions data may be cascaded from the parent organisation. However, no specific information regarding such initiatives or targets has been provided. In the context of the animal health industry, companies are increasingly recognising the importance of sustainability and climate action. While Boehringer Ingelheim Animal Health USA Inc. has not yet disclosed its emissions or reduction strategies, the broader industry trend indicates a growing commitment to addressing climate change and reducing environmental impact.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Boehringer Ingelheim Animal Health USA Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
